Skip to main content
SONOSCAPE MEDICAL CORP. logo

SONOSCAPE MEDICAL CORP. — Investor Relations & Filings

Ticker · 300633 ISIN · CNE100002P91 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2025-09-05 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300633

About SONOSCAPE MEDICAL CORP.

https://www.sonoscape.com

SonoScape Medical Corp. specializes in the research, development, and manufacturing of advanced medical diagnostic equipment. The company's primary product portfolio includes high-definition ultrasound systems, flexible endoscopy solutions, and electrocardiography devices. SonoScape focuses on delivering innovative imaging technology to healthcare providers globally, ranging from portable diagnostic tools to comprehensive trolley-based systems. Their ultrasound range covers various clinical applications such as cardiology, obstetrics, and radiology, while their endoscopy division provides high-resolution video processors and scopes for gastrointestinal and respiratory procedures. The company emphasizes continuous technological advancement and clinical efficiency to improve patient outcomes and diagnostic accuracy in diverse medical settings.

Recent filings

Filing Released Lang Actions
2025年员工持股计划（草案）
Capital/Financing Update Classification · 95% confidence The document is a detailed draft of an employee stock ownership plan (员工持股计划) for the year 2025 by Shenzhen Kaili Biomedical Technology Co., Ltd. It includes comprehensive information about the plan's purpose, principles, participants, funding sources, stock sources, pricing, scale, duration, lock-up period, performance assessment, management structure, and rights and obligations of participants. The document is lengthy (15,000 characters) and contains substantive content about the employee stock ownership plan itself, not merely an announcement or summary. It is not a financial report, earnings release, or regulatory filing. It is a detailed plan document related to capital structure and employee shareholding. According to the filing definitions, this fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including employee stock ownership plans. Therefore, the document should be classified as CAP with high confidence.
2025-09-05 Chinese
监事会关于公司2025年限制性股票与股票期权激励计划相关事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board opinion on the company's 2025 restricted stock and stock option incentive plan. It discusses compliance with relevant laws and regulations, eligibility of incentive recipients, and the plan's alignment with shareholder interests. It does not contain financial statements or detailed financial data, nor is it an announcement of a report publication. The content focuses on governance and regulatory compliance related to an equity incentive plan. This fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and does not match other more specific categories like Remuneration Information or Proxy Solicitation, which would require more detailed compensation or voting materials. The document length is short and it is not a report or announcement of voting results. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2025-09-05 Chinese
北京市中伦（深圳）律师事务所关于公司2025年员工持股计划（草案）的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a company's 2025 employee stock ownership plan (ESOP) draft. It extensively discusses the legal compliance, procedures, and governance related to the employee stock ownership plan, including details about the plan's structure, participants, funding, lock-up periods, and management. The document is not a financial report, earnings release, or regulatory filing about financial results. It is a legal opinion specifically about the employee stock ownership plan, which is a form of capital/financing update related to the company's equity and employee incentives. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed legal analysis, not just an announcement or certification, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2025-09-05 Chinese
2025年限制性股票与股票期权激励计划自查表
Regulatory Filings Classification · 95% confidence The document is a compliance self-check form related to a 2025 restricted stock and stock option incentive plan for Shenzhen Kaili Biomedical Technology Co., Ltd. It contains detailed compliance questions and confirmations about the stock incentive plan, including regulatory adherence, performance metrics, and procedural compliance. The document is relatively short (4087 characters) and is a checklist or self-assessment rather than a full report or announcement. It does not contain financial statements, audit opinions, or voting results. It is not a report publication announcement or a certification letter but a regulatory compliance document related to stock incentive plans. Given the nature of the content, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2025-09-05 Chinese
董事会薪酬与考核委员会关于公司 2025 年员工持股计划相关事项的核查意见
Remuneration Information Classification · 95% confidence The document is a formal opinion from the Board's Remuneration and Assessment Committee regarding the company's 2025 Employee Stock Ownership Plan (员工持股计划). It discusses compliance with relevant laws and regulations, the legality and effectiveness of the plan's procedures, and the benefits of the plan for employee incentives and company development. There is no financial data, audit information, or report publication mentioned. The content focuses on remuneration-related matters, specifically the employee stock ownership plan, which falls under executive compensation and incentive schemes. Therefore, the document best fits the Remuneration Information category (DEF 14A). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2025-09-05 Chinese
第四届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the tenth meeting of the fourth board of directors of Shenzhen Kaili Biomedical Technology Co., Ltd. It details the approval of various employee stock ownership plans and stock option incentive plans, as well as authorization requests to the shareholders' meeting. The document includes voting results and procedural details about the board meeting. It does not contain financial statements or detailed financial performance data, nor is it a transcript or presentation. It is a regulatory announcement about board decisions and upcoming shareholder meeting proposals. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2025-09-05 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.